April 3, 2025 07:11 AM EDTUpdated 07:39 AM
R&D

Sarep­ta, Roche pause Ele­v­idys tri­als in Eu­rope fol­low­ing pa­tient death

Ayisha Sharma

News Reporter

Sarep­ta and Roche are hit­ting the brakes on three tri­als of their Duchenne gene ther­a­py Ele­v­idys in re­sponse to a re­quest by the Eu­ro­pean Med­i­cines …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

FDA will con­sol­i­date to five 'shared ser­vices of­fices,' ac­cord­ing to memo to Hill staffers

Roche plans Phase 3 for its lat­est Alzheimer’s drug at­tempt af­ter un­veil­ing more ear­ly da­ta

FDA ap­proves Am­gen's Up­liz­na in IgG4-re­lat­ed dis­ease

DOJ at­tor­ney says Boehringer In­gel­heim has 'tremen­dous lever­age' in IRA ne­go­ti­a­tions

Trump has tout­ed Right to Try as a life­saver. Sev­er­al gov­ern­ment staff sup­port­ing it were just let go

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times